Open access peer-reviewed chapter

Strategies to Develop Cyclodextrin-Based Nanosponges for Smart Drug Delivery

Written By

Gjylije Hoti, Silvia Lucia Appleton, Alberto Rubin Pedrazzo, Claudio Cecone, Adrián Matencio, Francesco Trotta and Fabrizio Caldera

Submitted: 13 May 2021 Reviewed: 27 August 2021 Published: 21 September 2021

DOI: 10.5772/intechopen.100182

From the Edited Volume

Smart Drug Delivery

Edited by Usama Ahmad, Md. Faheem Haider and Juber Akhtar

Chapter metrics overview

417 Chapter Downloads

View Full Metrics


In recent years, the development of various cyclodextrin (CD)-based nanosponges (NSs) has gained great importance in the controlled and-or targeted release of drugs due to their versatility and simple preparation. In this chapter, an introduction of different administration routes is explained. Further, different ways to obtain CD-NSs and their classification are shown with a brief explanation of the characterization of the inclusion complexes. Finally, illustrative examples in diverse processes or diseases will be reviewed and explained to demonstrate the potential of CD-NSs. Therefore, this division will serve to compile information on CD-NSs in recent years and to illustrate to readers how to generate and apply different derivatives of interest.


  • Cyclodextrin nanosponges
  • drug delivery
  • synthesis
  • nanocarrier
  • release

1. Introduction

Society demands better treatments for each disease and therefore the industry tries to obtain them. Novel drugs with better bioactivity are researched to achieve the best result in our bodies. However, several novel drugs present problems related to their chemical properties that prevent them from being used as a pharma or nutraceutical product. The molecule can be unstable in water solution, and/or easily oxidized, and presents poor bioavailability. Different strategies might improve the current therapy. One possibility is to find a good formulation, which stabilizes the drug or carries it to the desired tissue. Moreover, the adverse effect due to the dosage can also be reduced. For this reason, a great number of carriers are been proposed to challenge the previous problems.

One of them is called cyclodextrin (CD), truncated cone-shaped oligosaccharides made up of α-(1→4) linked glucopyranoside units with six, seven and eight glucose units, α, β and γ-CD, respectively [1, 2]. A derivative called 2-Hydroxypropyl-βCD (HPβ-CD) is used as an orphan drug for Niemann Pick disease type C [3, 4]. Complexes formed of molecules and cyclodextrins (CDs) are called “inclusion complexes”. Generally, CDs encapsulate poorly water-soluble compounds and hydrophobic moieties of amphiphilic molecules. Nevertheless, the solubility of these complexes not only depends on the CD used but also on different factors such as pH or guess molecule [5, 6, 7, 8]. The capacity of CDs to increase solubility and protect several molecules has increased their use in the pharmaceutical and food industries [1, 9, 10].

However, the improvement achieved by adding CDs is sometimes insufficient. Then, researchers developed a novel material based on these excipients baptized as Cyclodextrin-based Nanosponge (CD-NS), innovative cross-linked polymer structures with a three-dimensional network, and with a crystalline and amorphous structure, spherical and possessing good swelling properties [11]. Recent reviews [12, 13, 14] point to their wide potential and minimal toxicity [15, 16]. Some applications of these polymers include i) increasing the apparent solubility of poorly soluble drugs, ii) modulating drug release and activity, iii) protecting drugs against several agents, iv) enhancing bioactivities, v) absorbing contaminants ability, vi) delivering the drug, etc.

Cross-linking CDs brings significant benefits to CD-NSs compared with the respective native CDs. In general, CD-NSs can form complexes with a series of different molecules due to their structure. They achieve a hindered diffusion of loaded guest molecules, thus promoting slower release kinetics [17, 18]. Another important property of CD-NSs is that they can be easily recovered from aqueous media and recycled. Although they are insoluble, soluble hyperbranched NS can also be synthesized [19]. Finally, one of their principal disadvantages has been recently solved, they have been tested as a good carrier not only for small molecules but also for higher ones like proteins [20, 21].

This chapter tends to be a first step for the researcher who starts with CD-NSs: i) an introduction of the routes of administration, including advantages and disadvantages is explained, ii) an explanation about the various types of CD-NSs, including its synthesis and classification is written, iii) the different ways to characterize the inclusion complexes are reported and iv) examples of smart delivery are displayed as an encourage study to demonstrate their potential.


2. Routes of administration, advantages, and disadvantages

The choice of the route of administration is crucial as it dramatically affects drug bioavailability and thus requires specific delivery strategies. Parenteral routes include intravenous, intramuscular, and subcutaneous routes, whereas the enteral routes are the oral, sublingual, and rectal routes [22]. Others are inhalation, intranasal, etc. [23]. In this section, each route will be described briefly and special attention will be paid to the oral route, which is the most desired but, at the same time, the most challenging.

When administered via intravenous injection (IV), the drug reaches the systemic circulation directly bypassing absorption and carrying out its effect rapidly. This route is ideal for unstable or scarcely absorbed drugs (e.g. blood products), and irritating drug formulations, the administration of which via subcutaneous and intramuscular routes will be painful. It is also intended for patients who are not able to take the formulations orally, due to mental disorders, nausea, or vomiting.

Intramuscular injection (IM) can involve various muscles, including the gluteal muscle to which up to 5 ml of the formulation can be administered. Via this route, aqueous or oil-based solutions, suspensions, and emulsions are accepted. Aqueous solutions are generally absorbed in 10–30 minutes, whereas drugs insoluble at interstitial pH or suspended in oil-based solutions present a long time of absorption. Vascularisation of the muscle, the volume, and the osmolarity of the injected formulations also affect the absorption time. A depot preparation of the drug can be given via this route with a sustained release of the drug into the bloodstream. IM injection is selected when the drug has a low oral bioavailability or when the patient is not compliant. Vaccines are also administered via this route.

Subcutaneous injections can be given in the forearm or abdomen. Up to 2 ml of the formulation can be administered. Together with aqueous solutions and suspensions, adrenalin can be added to induce vasoconstriction and therefore increase the residence time of drugs (e.g. local anesthetics) or hyaluronidase to make the extracellular matrix more fluid, thus improving the absorption rate.

The absorption rate is extremely variable as it is influenced by the blood flow. Subcutaneous injections are also used for depot formulations. It is easy to administer and requires minimal skills, thus allowing self-administration. Insulin and heparin are given via this route.

Among all, oral delivery has been recognized as the most attractive route, as it is cheap, simple, accepted by patients, requires fewer sterility restrictions, and offers more possibilities in the design of the formulation (including sustained and controlled delivery) [24]. It is used for drugs with topical action in the gut and systemic effects when they reach the bloodstream. However, it is not suitable for emergencies in which an immediate effect is fundamental.

Over the past few years, many efforts have been made to develop oral delivery systems able to overcome the obstacles in the gastrointestinal tract (GI) in which the mechanism of absorption is complex with multiple levels of barriers [24].

There is a long list of variables that influence the GI absorption of drugs, which are grouped in technical challenges, physicochemical properties of the drug, and environmental factors [25].

The technical challenges concern the pharmaceutical form, i.e. liquid or solid. In solid forms, the rate and extent of disintegration, and dissolution of the formulation are important to a drug, and to carry out its effect, needs to be in a solution for developing the absorption.

Most drugs are absorbed in the small intestine, characterized by a large surface area of absorption and having a crucial influence on bioavailability.

The walls of the GI tract are characterized by the presence of mucus, which has been a target for drug delivery systems (DDS) capable of mucopenetration or mucoadhesion [24]. Mucopenetration consists in regulating the hydrophobicity/hydrophilicity of the carrier’s matrix or combining mucolytic enzymes to promote drug penetration. On the contrary, mucoadhesive carriers, which have attracted significant attention [26, 27, 28], can adhere to mucus, thus increasing the residence time. CD NSs have proven to possess this property, making them particularly promising for oral delivery [20].

Last but not least, the first-pass effect should be borne in mind when dealing with the oral route as it is certainly a limiting factor. It refers to the metabolism (mainly in the liver) of the drug before it reaches the systemic circulation, which may lead to a drop in bioavailability [29]. For this reason, several drugs are administered via other enteral routes (e.g. rectal and sublingual).

The sublingual route offers the benefit of bypassing the first-pass effect due to the passive diffusion through the highly permeable mucosa underneath the tongue. It is simple with a low risk of infection and the effect is rapid. Nitroglycerin is administered via this route.

The rectal route exploits the highly vascularized rectal mucosa for drug absorption. The first-pass effect is partially avoided. It is indicated for patients with gastrointestinal motility problems, nausea, vomiting, and children.

Inhalation is used to obtain a rapid effect as the drug crosses the large surface area of the respiratory tract epithelium and reaches the systemic circulation. It avoids the first-pass metabolism. The particle size and morphology of the formulation inhaled are crucial. It is mainly used for the treatment of respiratory diseases. The intranasal route enables the drug to be absorbed via passive diffusion across the highly-vascularised respiratory epithelium directly into the systemic circulation. Nasal decongestants and anti-allergic drugs are administered via this route (Table 1).

Route of administrationAdvantagesDisadvantages
  • easy

  • safe

  • cheap

  • not Emergency therapy

  • not for GI-sensitive drugs (unless they are encapsulated

  • first pass effect

  • risk of interaction with food and drugs

  • rapid effect

  • suitable for emergency therapy

  • uncertain dosage

  • for pediatric use

  • for patients with impaired GI function

  • risk of irritation

  • unpredictable absorption

  • rapid absorption

  • suitable for general anesthesia and emergency therapy

  • risk of irritation

  • specific equipment is needed

  • suitable for emergency therapy

  • adjustable

  • accurate dosage

  • complications due to rapid onset

  • allergic reactions

  • rapid absorption

  • systemic administration of hydrophilic drugs

  • administration of sustained-release formulations

  • small volumes

  • painful

  • care must be taken to avoid veins and arteries

  • risk of infections and abscesses

  • rapid absorption

  • administration of sustained-release formulations

  • administration of very small volumes

Table 1.

Advantages and disadvantages of the main routes of administration.


3. Synthesis and classification of CD-NSs

The choice of appropriate synthetic conditions, allowed to obtain both water-soluble and water-insoluble polymer products, known also as CD-NSs or insoluble, and branched or soluble polymer [30, 31, 32]. The latter case allowed to overcome the limits of pristine CDs in terms of solubility in water and specific organic solvent, while the resulting formation of a three-dimensional cross-linked network was related to the presence of interstitial spaces among the monomers [33]. In this regard, the nature of the cross-linker and its amount in respect to the CD, ratio which defines the so-called cross-linking density, are presented to have a great impact on the properties and structure of the final material [34]. Also, being said interstices wider and more hydrophilic in respect to the cavities of CDs, a wider hosting capability was observed as a result.

3.1 General synthesis protocol

The most common method announced for the synthesis of CD based polymers, is characterized by employing a suitable solvent which could be either organic solvent or, in specific cases water, for the dissolution of the CDs. Afterwards, under continuous stirring, the chosen linking agent is added to the solution. Nevertheless, when required, the introduction of a catalyst occurs before the linking agent, and in specific cases, an increase in temperature is necessary to start the cross-linking reactions. The use of an ultrasound bath instead of stirring was also considered [35]. Eventually, either a sol–gel process or a precipitation polymerization can be observed, leading to the formation of a monolithic block or a precipitate, respectively. Also, in those cases in which the cross-linker is in the liquid form, and able to solubilize the CD, a melt polymerization can be performed [36, 37].

Once the synthesis is completed, the solvent, the catalyst, eventual unreacted monomers, and by-products are removed from the synthesized product by purification with water or other volatile solvents. In the end, a dry solid powder is collected [37, 38, 39]. Another well-known approach to synthesize CD-NSs is achieved through simple dehydration reactions. In this case, the CDs and the cross-linker, which is usually an acid bearing two or more carboxylic groups, are solubilized in water. After the addition of a suitable catalyst, the solution is heated to remove the water introduced as solvent as well as the water released as a by-product of the cross-linking condensation reaction. Moreover, the use of vacuum together with the temperature allows to shift the equilibrium of the reaction toward the products [40, 41]. Besides, less used synthetic routes report the use of interfacial or radical polymerization. In the first case, two immiscible phases such as a water solution of CD and a chlorinated solvent solution containing the chosen cross-linker, are mixed and stirred vigorously. The cross-linking occurs rapidly at the interface of the immiscible phases, and a precipitate is obtained [39]. While in the second case, a multistep procedure involving also preliminary derivatization of CD was displayed [42].

3.2 General classification

In general, based on the technological evolution of these materials, CD-NSs can be classified into four generations, considering their chemical composition and properties [19]. The first generation comprises all those NSs synthesized by a simple one-step reaction of CDs with a cross-linker. This generation was further divided into sub-categories according to the chemical nature of the linking molecules adopted for the synthesis. In this frame, carbonate, ester, ether, and urethane types are the most reported. These specific types of NSs will be described in more detail in the following paragraphs. Subsequently, the introduction of specific functions such as charge or luminescence to the final polymer structure defined the second generation of NSs. These materials displayed more complex polymer architectures achieved either via pre- or post-synthesis functionalization. In the first case, the introduced functions were limited to the surface of the polymer, whereas in the second case a more homogeneous distribution was observed. Referring to the division into generations, the 3rd generation deals with stimuli-responsive NSs, able to modulate their behavior (for example increasing/decreasing a drug release) according to the external environment.

3.2.1 CD-based polyurethane NSs

Urethane, or carbamate, CD-NSs are synthesized by reacting CDs (or a different dextrin) with a suitable diisocyanate as, for example, hexamethylene diisocyanate (HDI), toluene–2,4-diisocyanate (TDI). The reaction scheme is reported below (Figure 1, inset a). The resulting NSs are usually characterized by a rigid structure and a negligible swelling in water (in comparison with other CD-NSs), and organic solvent and high resistance to chemical degradation. Carbamate CD-NSs, were originally developed by Li and Ma for the treatment of wastewaters, as an alternative for activated carbon. They demonstrated with NSs remarkable performances in the removal of organic molecules such as p-nitrophenol reducing concentration of waste from 10−7–10−9 M to ppt level. The surface area was usually lower than activated carbon, (1–2 m2/g, two orders of magnitude) but it is supposed that organic molecules can be adsorbed, diffuse through the surface, and be absorbed inside the bulk of NSs [43].

Figure 1.

Schematic synthesis of a) CD-based polyurethane NSs and b) CD-based polycarbonate NSs.

The good affinity of organic molecules showed for pollutants [44], is also demonstrated by the application of urethane NSs in the complexation with biologically relevant compounds, such as bilirubin or amino acids. In 2006, Tang et al. evaluated the difference in absorption of aromatic amino acids and branched-chain amino acids: the absorption of branched-chain amino acids was negligible whereas NSs absorbed 24% of the aromatic amino acids.

In previous works the same polymer was tested for the absorption of bilirubin, reducing the initial concentration of bilirubin (40 mg/l) up to 92.6% after the addition of the NS [45].

3.2.2 CD-based polycarbonate NSs

Polycarbonate CD-NSs are usually synthesized using active difunctional carbonyl compounds such as 1,1′-carbonyldiimidazole, triphosgene, and diphenylcarbonate (Figure 1, inset b). Since the resulting CD NSs present carbonate bonds between CD monomers, these NSs present short cross-linking bridges and, consequentially, a reduced swelling ability (if compared to CD- based polyesters NSs, for example) and good stability to acidic solutions. The affinity to organic molecules and the surface area are comparable to carbamate NS [46]. The ability of β-CD carbonate NS to remove from wastewater chlorinated persistent organic pollutants (also known as POP) was investigated by Trotta and Cavalli in 2009 [47]: the absorption efficiency was higher than the average of activated carbon. For the specific case of hexachlorobenzene the NS was capable of removing around 99.5% of the pollutant.

An interesting method to evaluate the degree of cross-linking of carbonate β-CD NSs, employing infrared and Raman spectroscopy, was described by Castiglione et al. [48]. Data from spectroscopic analysis and chemical computation demonstrated a correlation between the intensity of carbonyl absorption peak and the degree of cross-linking: the degree of cross-linking increased with the amount of cross-linker, in total agreement with the stoichiometry. Dealing with sugar-based predominantly amorphous materials, the reported method represents a valid and advantageous alternative to x-ray. The crosslinking density or the amount of crosslinker, strongly influences the stiffness and elastic properties of the NSs. Rossi et al. demonstrated in their study that the mechanical features of the NSs can be easily tuned by changing the molar ratio CD/cross-linker, on the other hand, the CD used for the synthesis does not affect the mechanical properties of the final NS [34, 49].

3.2.3 CD-based polyester NSs

Ester CD-based NSs are synthesized using dianhydrides or di/polycarboxylic acids, such as pyromellitic dianhydride (PMDA), ethylenediamine- tetraacetic dianhydride (EDTA dianhydride), butanetetracarboxylic dianhydride, citric acid [46, 50].

Dissimilarly from polycarbonate and polyurethane NSs, polyester NSs are generally able to absorb remarkable amounts of water (up to 25 times/g dry sample), and form stable hydrogels. Similarly as seen before with mechanical properties, the swelling capability of the CD-NSs is generally dependent on the degree of cross-linking. The swelling capability is usually inversely proportional to the density of cross-linking: the lower the degree of cross-linking, the higher the water uptake. The structure of the material dramatically influences chemical stability. Ester NSs are subjected to hydrolysis in aqueous media more easily than polycarbonate and polyurethane NSs. The structure is remarkably interesting because of the presence of free carboxyl groups in their chemical structure, moieties that can be exploited for the absorption of cations, using the material as an ionic exchange resin.

There are in literature many examples of the formation of complexes with a metal cation. The metal ions complexation ability of pyromellitic NSs is studied by Berto et al. in for different metal cations, such as Al3+, Mn2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Pd2+.

In most cases, pyromellitic NSs were found to be capable of absorbing more than 70% of the tested cation [51].

A similar test of removing heavy metals from wastewaters, crosslinking also CDs with citric acid, is performed by Rubin Pedrazzo et al. in 2019 [52]. At a metal concentration of 500 ppm, the pyromellitic NSs (substituted before absorption with Na+) exhibited a higher retention capacity than the citrate NSs. At lower metal concentrations (≤ 50 ppm) both the citrate and the pyromellitic NSs showed high retention capacities (up to 94% of the total amount of metal). While in the presence of interfering sea water salts, the citrate NSs were able to selectively adsorb a significantly higher amount of heavy metals than the pyromellitic NSs.

For ester NSs, similar studies of the correlation of cross-linking degree with properties are performed. Surprisingly, the highest cross-linking degree was observed in the sample prepared using the molar ratio 1: 6, CD: PMDA [53].

Higher contents of cross-linker, molar ratios like 1:8 and 1:10, led to a decrease of the degree of cross-linking; this is possibly related to the steric hindrance generated by the pyromellitic units linked to CDs. Interestingly, by working under limited dilution conditions during the reaction and with an even lower CD/cross-linker ratio (e.g., 1:2 molar ratio), it is possible to obtain a hyper-branched water-soluble polymer [54]. As already described for carbonate NSs, Raman and Brillouin scattering experiments permitted Rossi et al. to evaluate a relationship between the mechanical characteristics of the polyester pyromellitic β-CD NS and the molar ratios CD/cross-linker: as seen before, stiffness and elasticity of the polymeric structure can be tuned by varying the amount of cross-linker [49].


4. Inclusion complex preparation and analysis

4.1 Preparation of inclusion complexes

Once the CD-NS is ready, the inclusion complex can be obtained by several procedures [55] as its summarized in Figure 2. Firstly, it is performed the classical mixing of drug and CD-NS in a solvent, commonly water for 24 h to form the complexes. In this procedure, we should consider the insoluble or soluble nature of our complexes. Depending on this, the desire fraction is purified. Using kneading, the drug and the CD-NS are mixed in a mortar with an appropriate quantity of water or another solvent to form the complexes. At this point, other additional techniques are used to form the powder: The solvent can be removed using lyophilization, co-evaporation, or spray-drying procedures.

Figure 2.

Different methods to prepare inclusion complexes.

4.2 Analysis of inclusion complexes

Different techniques can be employed to characterize not only inclusion complexes but also CD-NS. For information purposes, we will name some of them and briefly explain their possibilities [56, 57]:

4.2.1 Ultraviolet/visible spectroscopy

UV–vis is a simple, easy, and fast method for studying the host-guest complexation when its formation changes any particularity of the spectrum of a guest molecule or to check the solubilization efficacy [14, 16, 58, 59].

4.2.2 Fourier-transform infra-red (FTIR)

This technique is usually used in solid complexes, generally in the range of 400–4000 cm−1, although it depends on the studied drug [58, 60]. Changes in the characteristics bands of the guest molecule or shifts in the wavenumber can indicate the formation of the complex. In addition, the same principle can be used to follow the CD-NS synthesis.

4.2.3 Nuclear magnetic resonance (NMR) spectroscopy

NMR is one of the most useful procedures to obtain complete analytical information of the CD-NS and the complex formed. An alteration in the chemical shift of the protons occurs when the drug enters the CD-NS providing specific information about the orientation of the guest molecule inside the cavity.

4.2.4 Thermogravimetric analysis (TGA)

TGA determines the changes of weight to temperature increases. The comparison of the weight loss profile of pure components, physical mixture, and the complex shows differences correlatives to the complex formation. A stage on TGA around 300°C is found in CD-NS due to CD decomposition [59].

4.2.5 Differential scanning calorimetry (DSC)

It can provide detailed information about their physical and energetic properties. The comparison of the thermal curves of single components, their physical mixture, and the presumed inclusion compound ought to provide insight into modifications and interactions due to the formation of the inclusion complex. The change that occurs in the fusion point of the guest molecule is usually hiding by the complex formation, while it remains in the physical mixture. This, and several modifications in the shape and temperature peak of the CD dehydration and/or with the disappearance of the drug melting peak among others, are proves of the complexation.


5. Applications in smart drug delivery

5.1 Improving solubility and controlled release of drugs

5.1.1 CD-based polyurethane NSs

Another study showed the capability of CD polyurethane to reduce the levels of natural product contaminants, particularly, Ochratoxin A (OTA) from spiked solutions between 1 and 10 μgL-1 [61]. Following the attracted considerable interest that these polymers have shown in their use for water purification systems [62] and drug delivery [63], there were further done several chemical modifications on the CD NSs. Even though the modified CD NSs were used to enhance the properties and usefulness of CD NSs, their characterization at the molecular level remained a challenge. Therefore, a study described the structural characterization at the molecular level of both, native CD nanosponge polyurethanes and bionanosponge polyurethane cyclodextrin nanocomposite (pMWCNT-CD/Ag-TiO2) showing a great antibacterial and antifungal activity. The greatest antimicrobial activities were in the case of the developed polyurethane nanocomposite (pMWCNT-CD/Ag-TiO2). Consequently, it was concluded that this developed synthesis can be considered an active antimicrobial compound [64]. Another potential application of CD polyurethane polymer is as immobilization supports in enzyme catalysis. The lipase was immobilized into the aforementioned polymers via physisorption. It is observed an improvement in the stability and catalytic activity of lipase, knowing that the enzymes are generally unstable, insoluble in organic solvents, and sensitive. Accordingly, this study presented the chance to prepare immobilized biocatalysts with tunable catalytic activities attributed to the alteration of reaction conditions [65]. Further research was focused on the novel polyurethanes containing simultaneously β-cyclodextrin (β-CD), β-glycerophosphate groups, and hexamethylenediisocyanate (HDI). This polymer developed was used to complex the delivering therapeutic agents such as antibiotic ciprofloxacin. It was observed an improvement of the drug release in the case of the drug-polymers complexation than that of the free drug [63].

5.1.2 CD-based polycarbonate NSs

CD-based polycarbonate NSs synthesized using carbonyldiimidazole (CDI) showed antimicrobial activity against various microorganisms such as E. coli, S. aureus, P. aeruginosa, S. typhi, C. albicans, and Clostridia, when compared with Ciprofloxacin that was used as a standard drug. The formulations were prepared by polymer condensation, and interfacial phenomenon, and were effective for 6 months at a condition of 40°C and 75% of relative humidity [66]. This type of CD NSs was further used to deliver and increase the activity of several anticancer drugs such as paclitaxel [67], bortezomib [68], flutamide [69], tamoxifen [70], etc. Following their high potential to entrap a variety of molecules, the β-CD/CDI NSs were also used to deliver and improve the solubility and dissolution of paliperidone, an antipsychotic drug for the treatment of schizophrenia [71]. Further, rilpivirine is used for the treatment of HIV infection but has low aqueous solubility. Therefore, the β-CD/CDI NSs presented a strategy to improve this drawback and also the bioavailability and dissolution rate [72]. The antioxidant activity of kynurenic acid, an endogenous substance, was improved by loading it in β-CD/CDI NSs. The higher antioxidant activity was observed because of the increment in solubilization of kynurenic acid [60]. CD-based polycarbonate NSs synthesized using diphenyl carbonate (DPC) were used to overcome the poor solubility and stability of Babchi oil that is known for possessing numerous activities such as antifungal, antibacterial, antiviral, antitumor, antioxidant, etc. [73]. Further, the bioactive properties of the piperine, an alkaloid with anti-microbial, anti-inflammatory, anti-cancer properties, etc., were protected by the β-CD/DPC NSs [74]. This type of NSs exhibited complexing ability toward nifedipine, as an oral calcium channel blocking agent that is used to treat angina pectoris and hypertension. It was observed an improvement in the oral solubility of nifedipine after its incorporation into NSs [75].

5.1.3 CD-based polyester NSs

CD-based Ester NSs synthesized with pyromellitic dianhydride (PMDA) are well known for delivering, enhancing solubility, and preventing the degradation of various drugs such as Curcumin [76], Insulin [20], Resveratrol [77], Erlotinib hydrochloride [78], among others. Ethylenediaminetetraacetic dianhydride (EDTA) is another cross-linker to synthesize ester CD NSs. Based on HRMAS probe-heads in a high-resolution NMR spectrometer on the transport properties of Ibuprofen sodium salt (IP), it was found that these NSs can be utilized for the rational design of smart systems for drug delivery and controlled release [79]. The various applications of CD-based polyester NSs ranging from the environment to pharmacy, chemistry, agriculture, gene delivery, cosmetics, biocatalysis, brought to a detailed study on their cross-linking density. Being a very challenging task, it presented the effect of cross-linking density on β-CD NSs physicochemical properties. Flory-Rehner theory and rheology enabled the authors to understand the correlation between the structural features of NSs and their physicochemical properties, which is a key requirement for future applications [34].

5.2 Last generations of NSs for selected target drug delivery

Stimuli-responsive NSs represent the third generation, polymers that have been designed to modulate their behavior according to the surrounding environment. In this case, changes in the chemical structure of the material were reported to be triggered by pH, temperature gradients, or oxidative/reducing conditions. This feature was exploited for studying the targeted release of drugs, changes in color, and permeability. The use of glutathione (GSH) bioresponsive CD-NS was proposed as the system to deliver anticancer drugs or bioactive compounds [80, 81, 82, 83]. This is because GSH is 100 to 1000 times higher inside cells than that in the extracellular fluids and circulation. Indeed, in cancer cells, this concentration is almost higher being a good system for target drug delivery [84]. Different drugs such as doxorubicin [81] or bioactive compounds such as resveratrol [82] were tested showing a well-targeted drug delivery, and therefore is considered a promising therapy. In addition, the linkage of cholesterol was proposed as a good procedure for increase the targeted drug delivery of doxorubicin-loaded CD-NS [85].

Lastly, molecularly imprinted cyclodextrin-based polymers (Figure 3) define the fourth generation of NSs. Molecular imprinting represents a specific approach of inducing molecular recognition features to a three-dimensional polymer. This property can be achieved as a result of the presence of a template molecule introduced during synthesis. The template molecule after being removed from the polymer matrix leaves size-complementary vacancies, enabling the network to display high selectivity and affinity toward the chosen template. Eventually, molecularly imprinted CD-NSs are studied as suitable material to develop biosensors, drug delivery systems, catalysts, or synthetic antibody mimics [86, 87, 88]. A good example of this application is the L-Dopa as a novel possibility to treat Parkinson’s Disease. The molecularly imprinted CD-NSs showed a slower and more prolonged release profile than the non-imprinted NSs, indicating the good capacity to better complex L-Dopa than non-imprinted NS. The use of CDs in controlled and targeted drug delivery is shown in Table 2.

Figure 3.

Schematic synthesis of molecularly imprinted NSs.

DrugNanocarrier preparedOutcomeReferences
Controlled Drug Delivery
CD-based Polyurethane NSs
Erythromycin, vancomycin, and rifampicinβCD/HDILong-term sustained release of antibiotics.[89]
Mitomycin CϒCD/HDIProlonged anti-proliferative drug release.[90]
CD-based Polycarbonate NSs
CurcuminβCD/DMCIncreased anti-cancer drug solubility, and prolonged release.[91]
NorfloxacinβCD/DPCEnhanced anti-bacterial drug permeability.[92]
TamoxifenβCD/CDIIncreased anti-cancer drug solubility, and bioavailability.[93]
ResveratrolβCD/CDIIncreased the permeation, stability, and cytotoxicity against cancer[94]
CamptothecinβCD/DPCIncreased anti-cancer drug stability, and prolonged release.[95]
AcyclovirβCD/CDIEnhanced anti-viral drug loading, and prolonged release.[96]
TelmisartanβCD/DPCEnhanced anti-hypertensive drug solubility, improved bioavailability, and prolonged release.[97]
Babchi OilβCD/DPCEnhanced anti-bacterial essential oil solubility, photo-stability, and safety.[98]
RilpivirineβCD/CDI; PMDA; DPCEnhanced anti-viral drug solubility, and bioavailability.[99, 100]
PaclitaxelβCD/CDIEnhanced anti-cancer drug solubility, and pharmacological effect.[101]
SulfamethoxazoleβCD/CDIEnhanced anti-bacterial drug solubility.[102]
QuercetinβCD/DPCEnhanced anti-oxidative drug dissolution, and prolonged release.[103]
MelatoninβCD/CDIControlled drug release through skin.[104]
Kynurenic acidβCD/CDIEnhanced anti-oxidant potential of kynurenic acid.[105]
D-LimoneneβCD/DPCEnhanced anti-bacterial potential of the drug.[106]
Azelaic acidβCD/DPCEnhanced drug solubility, and its depigmenting action on the skin via antioxidant, and antityrosinase effect.[107]
ChrysinβCD/DPCEnhanced drug solubility, in-vitro antioxidant, and antitumoral activity.[108]
PaliperidoneβCD/CDIEnhanced antipsychotic drug solubility.[109]
Ferulic acidβCD/DPCEnhanced drug solubility, and bioavailability for the local therapy of vessels wall.[110]
FlutamideβCD/CDIEnhanced anti-cancer drug dissolution rate.[111]
GriseofulvinβCD/DPCEnhanced antifungal oral drug bioavailability, and improved dissolution rate.[112]
CD-based Polyester NSs
InsulinβCD/PMDAEnhanced anti-diabetic drug stability, and prolonged release.[113]
ImiquimodβCD/PMDAEnhanced drug aqueous solubility, and skin permeation capability.[114]
Acetyl salicylic acidβCD/PMDAEnhanced anti-inflammatory drug stability, and prolonged release.[115]
DoxorubicinβCD/PMDAImproved anti-cancer effectiveness.[116]
MeloxicamβCD/PMDAIncreased anti-inflammatory drug solubility, and wettability.[117]
Targeted Drug Delivery
DB103 - [2-(3, 4-dimethoxyphenyl)-3-phenyl-4H-pyrido]βCD/DPCEnhanced drug solubility, and bioavailability for the local therapy of vessels wall.[118]
L-DOPAβCD/CDI; PMDA (Molecularly imprinted cyclodextrin-based polymers)Enhanced drug solubility, and prolonged release.[119]
DoxorubicinTripeptide glutathione (GSH) nanosponge (NS)Enhanced antioxidant potential, and it is useful in targeting chemo-resistant tumors.[120]
StrigolactonesGSH/pH-NSEnhanced anticancer activity.[121]
Erlotinib hydrochloride (ETB)GSH-NSExhibited excellent drug uptake, extended drug release, in-vivo antitumor efficacy, and biodistribution.[122]

Table 2.

The use of cyclodextrin based nanosponges in drug delivery.

βCD, Beta Cyclodextrin; ϒCD, Gama Cyclodextrin; HDI, Hexamethylene diisocyanate; CDI, Carbonyldiimidazole; DMC, Dimethyl Carbonate; DPC, Diphenyl carbonate; PMDA, Pyromellitic Dianhydride.


6. Conclusions

CD-NSs are demonstrated to be safe, cheap, and biocompatible polymers. Consequently, several authors are focused on this field recently achieving novel applications. This chapter summarized the general information that will guide the advanced research to investigate the CD-NSs. Information about the routes of administration, synthesis protocols, recommendations, classifications, and applications of the novel synthesized materials, with special attention to targeted drug delivery, are mostly collected. It is shown the ability of CD-NSs to entrap drugs and to control their release from the matrix which can be modulated by different physicochemical agents.

As a remark, CD-NS is a good promise to improve the current problems in drug formulations and open novel strategies for drug delivery that identify the light in the future.



This work is the result of aid to postdoctoral training and improvement abroad (for Adrián Matencio, number 21229/PD/19) financed by the Fundación Séneca (Región de Murcia, Spain).


Conflict of interest

The authors declare no conflict of interest.


  1. 1. Matencio A, Navarro-Orcajada S, García-Carmona F, López-Nicolás JM. Applications of cyclodextrins in food science. A review. Trends Food Sci Technol 2020.
  2. 2. Szente L, Szejtli J. Cyclodextrins as food ingredients. Trends in Food Science & Technology 2004; 15: 137-142.
  3. 3. Matencio A, Alcaráz-Gómez MA, García-Carmona F, Arias B, López-Nicolás JM. Application of a simple methodology to analyze Hydroxypropyl-β-Cyclodextrin in urine using HPLC–LS in early Niemann–Pick disease type C patient. Journal of Chromatography B 2018; 1093-1094: 47-51.
  4. 4. Matencio A, Navarro-Orcajada S, González-Ramón A, García-Carmona F, López-Nicolás JM. Recent advances in the treatment of Niemann pick disease type C: A mini-review. International Journal of Pharmaceutics 2020; 584: 119440.
  5. 5. Matencio A, García-Carmona F, López-Nicolás JM. The inclusion complex of oxyresveratrol in modified cyclodextrins: A thermodynamic, structural, physicochemical, fluorescent and computational study. Food Chemistry 2017; 232: 177-184.
  6. 6. Matencio A, Bermejo-Gimeno MJ, García-Carmona F, López-Nicolás JM. Separating and Identifying the Four Stereoisomers of Methyl Jasmonate by RP-HPLC and using Cyclodextrins in a Novel Way. Phytochemical Analysis 2017; 28: 151-158.
  7. 7. Matencio A, Navarro-Orcajada S, García-Carmona F, Manuel López-Nicolás J. Ellagic acid–borax fluorescence interaction: application for novel cyclodextrin-borax nanosensors for analyzing ellagic acid in food samples. Food & Function 2018; 9: 3683-3687.
  8. 8. Matencio A, Caldera F, Rubin Pedrazzo A, Khazaei Monfared Y, K. Dhakar N, Trotta F. A physicochemical, thermodynamical, structural and computational evaluation of kynurenic acid/cyclodextrin complexes. Food Chemistry 2021; 356: 129639.
  9. 9. Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. International Journal of Pharmaceutics 2018; 535: 272-284.
  10. 10. Matencio A, Caldera F, Cecone C, López-Nicolás JM, Trotta F. Cyclic Oligosaccharides as Active Drugs, an Updated Review. Pharmaceuticals 2020; 13: 281.
  11. 11. Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based Nanosponges for Drug Delivery. J Incl Phenom Macrocycl Chem 2006; 56: 209-213.
  12. 12. Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: A critical review. Carbohydrate Polymers 2017; 173: 37-49.
  13. 13. Swaminathan S, Cavalli R, Trotta F. Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development. WIREs Nanomed Nanobiotechnol 2016; 8: 579-601.
  14. 14. Krabicová I, Appleton SL, Tannous M, et al. History of Cyclodextrin Nanosponges. Polymers (Basel) 2020; 12.
  15. 15. Shende P, Kulkarni YA, Gaud RS, et al. Acute and Repeated Dose Toxicity Studies of Different β-Cyclodextrin-Based Nanosponge Formulations. Journal of Pharmaceutical Sciences 2015; 104: 1856-1863.
  16. 16. Matencio A, Guerrero-Rubio MA, Caldera F, et al. Lifespan extension in Caenorhabditis elegans by oxyresveratrol supplementation in hyper-branched cyclodextrin-based nanosponges. International Journal of Pharmaceutics 2020; 589: 119862.
  17. 17. Caldera F, Tannous M, Cavalli R, Zanetti M, Trotta F. Evolution of Cyclodextrin Nanosponges. International Journal of Pharmaceutics 2017; 531: 470-479.
  18. 18. Trotta F, Caldera F, Cavalli R, et al. Synthesis and characterization of a hyper-branched water-soluble β-cyclodextrin polymer. Beilstein Journal of Organic Chemistry 2014; 10: 2586-2593.
  19. 19. Trotta F, Caldera F, Cavalli R, et al. Synthesis and characterization of a hyper-branched water-soluble β-cyclodextrin polymer. Beilstein Journal of Organic Chemistry 2014; 10: 2586-2593.
  20. 20. Appleton SL, Tannous M, Argenziano M, et al. Nanosponges as protein delivery systems: Insulin, a case study. Int J Pharm 2020; 590: 119888.
  21. 21. Deshmukh K, Tanwar YS, Sharma S, Shende P, Cavalli R. Functionalized nanosponges for controlled antibacterial and antihypocalcemic actions. Biomedicine & Pharmacotherapy 2016; 84: 485-494.
  22. 22. Paoletti R, Nicosia S, Clementi F, Fumagalli G. Farmacologia Generale e Molecolare. (UTET, ed.)., 2004.
  23. 23. Kim J, De Jesus O. Medication Routes of Administration. (StatPearls, ed.). StatPearls Publishing, 2021.
  24. 24. Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 2019; 11.
  25. 25. Fuccella LM, Perucca E, Sirtori C. Farmacologia clinica. (Mediche US, ed.)., 2006.
  26. 26. Boddupalli BM, Mohammed ZNK, Ravinder Nath A.1 DB. Mucoadhesive drug delivery system: An overview. J Adv Pharm Tech Res 2010.
  27. 27. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Development and Industrial Pharmacy 1997; 23: 489-515.
  28. 28. Gatti THH, Eloy JO, Ferreira LMB, et al. Insulin-loaded polymeric mucoadhesive nanoparticles: Development, characterization and cytotoxicity evaluation. Brazilian Journal of Pharmaceutical Sciences 2018; 54: 1-10.
  29. 29. Rowland M, Tozer TN. Clinical Pharmacokineticsand Pharmacodynamics Concepts and Applications. (Wilkins LW&, ed.)., 2011.
  30. 30. Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: A critical review. Carbohydrate Polymers 2017; 173: 37-49.
  31. 31. Chilajwar S V., Pednekar PP, Jadhav KR, Gupta GJC, Kadam VJ. Cyclodextrin-based nanosponges: A propitious platform for enhancing drug delivery. Expert Opinion on Drug Delivery 2014; 11: 111-120.
  32. 32. Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: A review. Acta Pharmaceutica 2013; 63: 335-358.
  33. 33. Kumar S, Dalal P, Rao R. Cyclodextrin Nanosponges: A Promising Approach for Modulating Drug Delivery. Colloid Science in Pharmaceutical Nanotechnology 2020.
  34. 34. Hoti G, Caldera F, Cecone C, et al. Effect of the cross-linking density on the swelling and rheological behavior of ester-bridged β-cyclodextrin nanosponges. Materials 2021; 14: 1-20.
  35. 35. Trotta F, Cavalli R, Tumiatti W, Zerbinati O, Roggero C, Vallero R. Ultrasound synthesis of nanosponges.pdf. 2006.
  36. 36. Trotta F, Cavalli R. Characterization and applications of new hyper-cross-linked cyclodextrins. Composite Interfaces 2009; 16: 39-48.
  37. 37. Cecone C, Hoti G, Krabicova I, et al. Sustainable synthesis of cyclodextrin-based polymers exploiting natural deep eutectic solvents. Green Chemistry 2020; 22: 5806-5814.
  38. 38. Trotta F. Cyclodextrin nanosponges and their applications. In: Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications. First., 2011, 323-42.
  39. 39. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein Journal of Organic Chemistry 2012; 8: 2091-2099.
  40. 40. Martel B, Ruffin D, Weltrowski M, Lekchiri Y, Morcellet M. Water-soluble polymers and gels from the polycondensation between cyclodextrins and poly(carboxylic acid)s: A study of the preparation parameters. Journal of Applied Polymer Science 2005; 97: 433-442.
  41. 41. Zhao D, Zhao L, Zhu C-S, Huang W, Hu J. Water-insoluble b-cyclodextrin polymer crosslinked by citric acid : synthesis and adsorption properties toward phenol and methylene blue. J Incl Phenom Macrocycl Chem 2009; 63: 195-201.
  42. 42. Lu D, Yang L, Zhou T, Lei Z. Synthesis, characterization and properties of biodegradable polylactic acid-β-cyclodextrin cross-linked copolymer microgels. European Polymer Journal 2008; 44: 2140-2145.
  43. 43. B. B. Mamba, Krause RW, Malefetse TJ, Gericke G, S. P. Sithole. Nanosponges for water purification. Clean Products and Processes 2. 2000; 2: 112-6.
  44. 44. B. B. Mamba, R. W. Krause, T. J. Malefetse GG e SPS. Cyclodextrin nanosponges in the removal of organic matter to produce water for power generation. 2008; 34: 657-60.
  45. 45. Zheng C, Huang X, Kong L, Li X, Zou H. Cross-linked beta-cyclodextrin polymer used for bilirubin removal. Chinese journal of chromatography, 2004; 22: 128-130.
  46. 46. Trotta F. Cyclodextrin Nanosponges and their Applications. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications 2011: 323-342.
  47. 47. Trotta F, Cavalli R. Characterization and application of new hyper-cross-linked cyclodextrins. Compos Interf 2009; 16: 39-48.
  48. 48. Castiglione F, Crupi V, Majolino D, et al. Inside new materials: An experimental numerical approach for the structural elucidation of nanoporous cross-linked polymers. Journal of Physical Chemistry B 2012; 116: 13133-13140.
  49. 49. Rossi B, Caponi S, Castiglione F, et al. Networking properties of cyclodextrin-based cross-linked polymers probed by inelastic light-scattering experiments. Journal of Physical Chemistry B 2012; 116: 5323-5327.
  50. 50. Caldera F, Tannous M, Cavalli R, Zanetti M, Trotta F. Evolution of Cyclodextrin Nanosponges. International Journal of Pharmaceutics 2017; 531: 470-479.
  51. 51. Berto S, Bruzzoniti MC, Cavalli R, et al. Synthesis of new ionic β-cyclodextrin polymers and characterization of their heavy metals retention. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2007; 57: 631-636.
  52. 52. Rubin Pedrazzo A, Smarra A, Caldera F, et al. Eco-Friendly β -cyclodextrin and Linecaps Polymers for the Removal of Heavy Metals. Polymers 2019: 1-15.
  53. 53. Crupi V, Fontana A, Giarola M, et al. Connection between the vibrational dynamics and the cross-linking properties in cyclodextrins-based polymers. Journal of Raman Spectroscopy 2013; 44: 1457-1462.
  54. 54. Trotta F, Caldera F, Cavalli R, et al. Synthesis and characterization of a hyper-branched water-soluble β-cyclodextrin polymer. Beilstein Journal of Organic Chemistry 2014; 10: 2586-2593.
  55. 55. Gharib R, Greige-Gerges H, Fourmentin S, Charcosset C, Auezova L. Liposomes incorporating cyclodextrin–drug inclusion complexes: Current state of knowledge. Carbohydrate Polymers 2015; 129: 175-186.
  56. 56. Mura P. Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: A review. Journal of Pharmaceutical and Biomedical Analysis 2014; 101: 238-250.
  57. 57. Mura P. Analytical techniques for characterization of cyclodextrin complexes in the solid state: A review. Journal of Pharmaceutical and Biomedical Analysis 2015; 113: 226-238.
  58. 58. Dhakar NK, Matencio A, Caldera F, et al. Comparative Evaluation of Solubility, Cytotoxicity and Photostability Studies of Resveratrol and Oxyresveratrol Loaded Nanosponges. Pharmaceutics 2019; 11: 545.
  59. 59. Matencio A, Dhakar NK, Bessone F, et al. Study of oxyresveratrol complexes with insoluble cyclodextrin based nanosponges: Developing a novel way to obtain their complexation constants and application in an anticancer study. Carbohydrate Polymers 2020; 231: 115763.
  60. 60. Dhakar NK, Caldera F, Bessone F, et al. Evaluation of solubility enhancement, antioxidant activity, and cytotoxicity studies of kynurenic acid loaded cyclodextrin nanosponge. Carbohydrate Polymers 2019; 224: 115168.
  61. 61. Appell M, Jackson MA. Sorption of Ochratoxin A from Aqueous Solutions Using β-Cyclodextrin-Polyurethane Polymer. Toxins 2012; 4: 98-109.
  62. 62. Leudjo Taka A, Pillay K, Yangkou Mbianda X. Nanosponge cyclodextrin polyurethanes and their modification with nanomaterials for the removal of pollutants from waste water: A review. Carbohydrate Polymers 2017; 159: 94-107.
  63. 63. Moreira MP, Andrade GRS, De Araujo MVG, Kubota T, Gimenez IF. Ternary cyclodextrin polyurethanes containing phosphate groups: Synthesis and complexation of ciprofloxacin. Carbohydrate Polymers 2016; 151: 557-564.
  64. 64. Taka AL, Doyle BP, Carleschi E, et al. Spectroscopic characterization and antimicrobial activity of nanoparticle doped cyclodextrin polyurethane bionanosponge. Materials Science& Engineering C 2020: 1-15.
  65. 65. Dhake KP, Karoyo AH, Mohamed MH, Wilson LD, Bhanage BM. Enzymatic activity studies of Pseudomonas cepacia lipase adsorbed onto copolymer supports containing β-cyclodextrin. Journal of Molecular Catalysis B: Enzymatic 2013; 87: 105-112.
  66. 66. Desai D, Shende P. Drug-Free Cyclodextrin-Based Nanosponges for Antimicrobial Activity. Journal of Pharmaceutical Innovation 2020: 11.
  67. 67. Mognetti B, Barberis A, Marino S, et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2012; 74: 201-210.
  68. 68. Allahyari S, Valizadeh H, Roshangar L, et al. Preparation and characterization of cyclodextrin nanosponges for bortezomib delivery. Expert Opinion on Drug Delivery 2020; 17: 10.
  69. 69. Allahyari S, Esmailnezhad N, Valizadeh H, et al. In-vitro characterization and cytotoxicity study of flutamide loaded cyclodextrin nanosponges. Journal of Drug Delivery Science and Technology 2021; 61: 1-7.
  70. 70. Torne S, Darandale S, Vavia P, Trotta F, Cavalli R. Cyclodextrin-based nanosponges: effective nanocarrier for Tamoxifen delivery. Pharmaceutical Development and Technology 2013; 18: 619-625.
  71. 71. Sherje AP, Surve A, Shende P. CDI cross-linked β -cyclodextrin nanosponges of paliperidone : synthesis and physicochemical characterization. Journal 2019.
  72. 72. Rao MRP, Chaudhari J, Trotta F, Caldera F. Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine. AAPS PharmSciTech 2018; 19: 2358-2369.
  73. 73. Kumar S, Pooja, Trotta F, Rao R. Encapsulation of Babchi Oil in Cyclodextrin-Based Nanosponges: Physicochemical Characterization, Photodegradation, and In Vitro Cytotoxicity Studies. Pharmaceutics 2018; 10:1-18
  74. 74. Garrido B, González S, Hermosilla J, et al. Carbonate-β-Cyclodextrin-Based Nanosponge as a Nanoencapsulation System for Piperine: Physicochemical Characterization. Journal of Soil Science and Plant Nutrition 2019; 19: 620-630.
  75. 75. Shringirishi M, Mahor A, Gupta R, Prajapati SK, Bansal K, Kesharwani P. Fabrication and characterization of nifedipine loaded β-cyclodextrin nanosponges: An in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology 2017; 41: 344-350.
  76. 76. Pushpalatha R, Selvamuthukumar S, Kilimozhi D. Cross-linked, cyclodextrin-based nanosponges for curcumin delivery - Physicochemical characterization, drug release, stability and cytotoxicity. Journal of Drug Delivery Science and Technology 2018; 45: 45-53.
  77. 77. Pushpalatha R, Selvamuthukumar S, Kilimozhi D. Carbonyl and carboxylate crosslinked cyclodextrin as a nanocarrier for resveratrol: in silico, in vitro and in vivo evaluation. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2018; 92: 261-272.
  78. 78. Momin MM, Zaheer Z, Zainuddin R, Sangshetti JN. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. Artificial Cells, Nanomedicine and Biotechnology 2018; 46: 1064-1075.
  79. 79. Ferro M, Castiglione F, Punta C, et al. Anomalous diffusion of Ibuprofen in cyclodextrin nanosponge hydrogels: an HRMAS NMR study. Beilstein Journal of Organic Chemistry 2014; 10: 2715-2723.
  80. 80. Rossi B, Venuti V, D’Amico F, et al. Toward an understanding of the thermosensitive behaviour of pH-responsive hydrogels based on cyclodextrins. Soft Matter 2015; 11: 5862-5871.
  81. 81. Daga M, Ullio C, Argenziano M, et al. GSH-targeted nanosponges increase doxorubicin-induced toxicity “in vitro” and “in vivo” in cancer cells with high antioxidant defenses. Free Radical Biology and Medicine 2016; 97: 24-37.
  82. 82. Palminteri M, Dhakar NK, Ferraresi A, et al. Cyclodextrin nanosponge for the GSH-mediated delivery of Resveratrol in human cancer cells. Nanotheranostics 2021; 5: 197-212.
  83. 83. Argenziano M, Lombardi C, Ferrara B, et al. Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells. Oncotarget 2018; 9: 35813-35829.
  84. 84. Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013; 2013: 972913.
  85. 85. Singh P, Ren X, Guo T, et al. Biofunctionalization of β-cyclodextrin nanosponges using cholesterol. Carbohydr Polym 2018; 190: 23-30.
  86. 86. Shende P, Kulkarni YA, Gaud RS, et al. Acute and repeated dose toxicity studies of different β-cyclodextrin-based nanosponge formulations. Journal of Pharmaceutical Sciences 2015; 104: 1856-1863.
  87. 87. Kyzas GZ, Lazaridis NK, Bikiaris DN. Optimization of chitosan and β-cyclodextrin molecularly imprinted polymer synthesis for dye adsorption. Carbohydrate Polymers 2013; 91: 198-208.
  88. 88. Deshmukh K, Tanwar YS, Shende P, Cavalli R. Biomimetic estimation of glucose using non-molecular and molecular imprinted polymer nanosponges. International Journal of Pharmaceutics 2015; 494: 244-248.
  89. 89. T. R. Thatiparti and H. A. Von Recum, “Cyclodextrin Complexation for Affinity-Based Antibiotic Delivery,” Macromol. Biosci., vol. 10, pp. 82-90, 2010.
  90. 90. S. R. Merritt, G. Velasquez, and H. A. Von Recum, “Adjustable release of mitomycin C for inhibition of scar tissue formation after filtration surgery,” Exp. Eye Res., vol. 116, pp. 9-16, 2013.
  91. 91. S. S. Darandale and P. R. Vavia, “Cyclodextrin-based nanosponges of curcumin: Formulation and physicochemical characterization,” in Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2013, vol. 75, no. 3-4, pp. 315-322.
  92. 92. C. Mendes, G. C. Meirelles, C. G. Barp, J. Assreuy, M. A. S. Silva, and G. Ponchel, “Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity,” Carbohydr. Polym., vol. 195, pp. 586-592, 2018.
  93. 93. S. Torne, S. Darandale, P. Vavia, F. Trotta, and R. Cavalli, “Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery,” Pharmaceutical development and technology, vol. 18, no. 3. pp. 619-625, 2013.
  94. 94. K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, “Cyclodextrin-Based Nanosponges for Delivery of Resveratrol: In vitro Characterisation, Stability, Cytotoxicity and Permeation Study,” AAPS PharmSciTech, vol. 12, no. 1, pp. 279-286, Mar. 2011.
  95. 95. S. Swaminathan et al., “Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity,” Eur. J. Pharm. Biopharm., vol. 74, pp. 193-201, 2010.
  96. 96. D. Lembo et al., “Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent’s antiviral efficacy,” Int. J. Pharm., vol. 443, pp. 262-272, Feb. 2013.
  97. 97. M. Rao, A. Bajaj, I. Khole, G. Munjapara, and F. Trotta, “In vitro and in vivo evaluation of β-cyclodextrin-based nanosponges of telmisartan,” J. Incl. Phenom. Macrocycl. Chem., vol. 77, pp. 135-145, Dec. 2013.
  98. 98. S. Kumar, Pooja, F. Trotta, and R. Rao, “Encapsulation of Babchi Oil in Cyclodextrin-Based Nanosponges: Physicochemical Characterization, Photodegradation, and In Vitro Cytotoxicity Studies,” Pharmaceutics, vol. 10, p. 169, Sep. 2018.
  99. 99. R. Zainuddin, Z. Zaheer, J. N. Sangshetti, and M. Momin, “Enhancement of oral bioavailability of anti- HIV drug rilpivirine HCl through nanosponge formulation,” Drug Dev. Ind. Pharm., vol. 43, no. 12, pp. 2076-2084, 2017.
  100. 100. M. R. P. Rao, J. Chaudhari, F. Trotta, and F. Caldera, “Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine,” AAPS PharmSciTech, pp. 2358-2368, 2018.
  101. 101. B. Mognetti et al., “In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation,” J. Incl. Phenom. Macrocycl. Chem., vol. 74, pp. 201-210, Dec. 2012.
  102. 102. G. Yaşayan, B. Şatıroğlu Sert, E. Tatar, and İ. Küçükgüzel, “Fabrication and characterisation studies of cyclodextrin-based nanosponges for sulfamethoxazole delivery,” J. Incl. Phenom. Macrocycl. Chem., vol. 97, pp. 175-186, 2020.
  103. 103. S. Anandam and S. Selvamuthukumar, “Fabrication of cyclodextrin nanosponges for quercetin delivery: physicochemical characterization, photostability, and antioxidant effects,” J. Mater. Sci., vol. 49, pp. 8140-8153, 2014.
  104. 104. M. Mihailiasa, F. Caldera, J. Li, R. Peila, A. Ferri, and F. Trotta, “Preparation of functionalized cotton fabrics by means of melatonin loaded β-cyclodextrin nanosponges,” Carbohydr. Polym., vol. 142, pp. 24-30, 2016.
  105. 105. N. K. Dhakar et al., “Evaluation of solubility enhancement, antioxidant activity, and cytotoxicity studies of kynurenic acid loaded cyclodextrin nanosponge,” Carbohydr. Polym., vol. 224, pp. 1-9, 2019.
  106. 106. O. Salehi, S. Masoud, and A. Rezaei, “Limonene loaded cyclodextrin nanosponge: Preparation, characterization, antibacterial activity and controlled release,” Food Biosci., vol. 42, pp. 1-9, 2021.
  107. 107. A. Kumar and R. Rao, “Enhancing efficacy and safety of azelaic acid via encapsulation in cyclodextrin nanosponges: development, characterization and evaluation,” Polym. Bull., vol. 78, pp. 5275-5302, 2021.
  108. 108. M. Sundararajan, P. A. Thomas, K. Venkadeswaran, K. Jeganathan, and P. Geraldine, “Synthesis and Characterization of Chrysin-Loaded β-Cyclodextrin-Based Nanosponges to Enhance In-Vitro Solubility, Photostability, Drug Release, Antioxidant Effects and Antitumorous Efficacy,” J. Nanosci. Nanotechnol., vol. 17, p. 10, 2017.
  109. 109. A. P. Sherje, A. Surve, and P. Shende, “CDI cross-linked β -cyclodextrin nanosponges of paliperidone : synthesis and physicochemical characterization,” Journal, 2019.
  110. 110. A. Rezaei, J. Varshosaz, M. Fesharaki, A. Farhang, and S. M. Jafari, “Improving the solubility and in vitro cytotoxicity (anticancer activity) of ferulic acid by loading it into cyclodextrin nanosponges,” pp. 4589-4599, 2019.
  111. 111. S. Allahyari et al., “In-vitro characterization and cytotoxicity study of flutamide loaded cyclodextrin nanosponges,” J. Drug Deliv. Sci. Technol., vol. 61, pp. 1-7, 2021.
  112. 112. S. M. Omar, F. Ibrahim, and A. Ismail, “Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste,” Saudi Pharm. J., vol. 28, pp. 349-361, 2020.
  113. 113. S. Lucia Appleton et al., “Nanosponges as protein delivery systems : Insulin, a case study,” Int. J. Pharm., vol. 590, pp. 1-11, 2020.
  114. 114. M. Argenziano et al., “In Vitro Enhanced Skin Permeation and Retention of Imiquimod Loaded in β -Cyclodextrin Nanosponge Hydrogel,” Pharmaceutics, vol. 11, no. 138, pp. 1-17, 2019.
  115. 115. P. K. Shende, F. Trotta, R. S. Gaud, K. Deshmukh, R. Cavalli, and M. Biasizzo, “Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with β-cyclodextrin and inclusion complexes of ASA with PMDA cross-linked β-cyclodextrin nanosponges,” J. Incl. Phenom. Macrocycl. Chem., vol. 74, pp. 447-454, 2012.
  116. 116. M. Argenziano et al., “Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models,” Cancers (Basel)., vol. 12, no. 162, pp. 1-19, 2020.
  117. 117. P. K. Shende, R. S. Gaud, R. Bakal, and D. Patil, “Effect of inclusion complexation of meloxicam with β-cyclodextrin-and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies,” Colloids Surfaces B Biointerfaces, vol. 136, pp. 105-110, 2015.
  118. 118. V. Coviello, S. Sartini, L. Quattrini, C. Baraldi, M. C. Gamberini, and C. La Motta, “Cyclodextrin-based nanosponges for the targeted delivery of the anti-restenotic agent DB103: A novel opportunity for the local therapy of vessels wall subjected to percutaneous intervention,” Eur. J. Pharm. Biopharm., vol. 117, pp. 276-285, 2017.
  119. 119. F. Trotta et al., “Molecularly imprinted cyclodextrin nanosponges for the controlled delivery of L-DOPA: perspectives for the treatment of Parkinson’s disease,” Expert Opin. Drug Deliv., vol. 13, no. 12, pp. 1671-1680, 2016.
  120. 120. M. Daga et al., “GSH-targeted nanosponges increase doxorubicin-induced toxicity ‘in vitro’ and ‘in vivo’ in cancer cells with high antioxidant defenses,” Free Radic. Biol. Med., vol. 97, pp. 24-37, 2016.
  121. 121. M. Argenziano et al., “Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells,” Oncotarget, vol. 9, no. 88, pp. 35813-35829, 2018.
  122. 122. M. M. Momin, Z. Zaheer, R. Zainuddin, and J. N. Sangshetti, “Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer,” Artificial Cells, Nanomedicine and Biotechnology, vol. 46, no. 5. pp. 1064-1075, 2018.

Written By

Gjylije Hoti, Silvia Lucia Appleton, Alberto Rubin Pedrazzo, Claudio Cecone, Adrián Matencio, Francesco Trotta and Fabrizio Caldera

Submitted: 13 May 2021 Reviewed: 27 August 2021 Published: 21 September 2021